New York Times: “The Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, according to a senior administration official.”
“In 2023, 14 peptides were removed from a list of products that the F.D.A. allows compounding pharmacies to produce. The pharmacies tailor products for individual patients’ needs. The peptides had not been approved by the F.D.A. as safe or effective and, in recent years, the agency had noted that they were increasingly being marketed with unproved claims that they had cosmetic, anti-aging and disease-fighting benefits.”
Save to Favorites